retatrutide liver STUDY: Novel “Triagonist” Resolved Steatosis in Over 85% of Patients with MASLD and Obesity Retatrutide: A Triple Agonist Shaping

This was a landmark moment because it represented global recognition of GLP-1 medications as a legitimate long-term treatment for obesity rather than a temporary or supplementary intervention

Contributor Information Jennifer Panganiban, Email: [email protected]

Autoimmune Disorders

Surgical enhancements, such as facelifts and eyelid lifts, can last for many years, while fillers and other nonsurgical treatments require periodic maintenance

Gut 46 , 622631 (2000)

When compared to other GLP-1 medicationssuch as liraglutide (Saxenda), dulaglutide (Trulicity), and exenatide (Byetta)semaglutide generally leads to more pronounced and sustained weight loss outcomes